When it comes to CLL/SLL treatment, what’s the difference between BTK inhibitors and BCL-2 inhibitors? Understanding how these treatment approaches work and how they fit into the treatment…
BTK degrader BGB-16673 reduced tumor burden in 85% of patients from a high-risk, hard-to-treat group with relapsed / refractory CLL. Dr. Stephan Stilgenbauer from Ulm University and colleagues…
This video explains 10 early signs and symptoms of diabetes that often go unnoticed. These include increased thirst, frequent bathroom breaks, recurrent infections, unexplained weight changes, and blurry…
This session dives into the etiopathogenesis of rheumatoid arthritis (RA). Learn about RA’s impact on joints, its genetic and environmental triggers, and the roles of T and B…
